_____________
The plan is to enroll six patients with MSI, regardless of their primary cancer diagnosis. This cohort will serve to generate hypothesis and initial data to plan a larger study. All analyses from this cohort will be exploratory
> As with most experiments
This isn't true. It's absolutely standard in earlier trials of investigational agents to not have any sort of control arm.
> there's a control group (6 patients).
This isn't true. Within the study you posted, there are two different cohorts, with different patient types included.
> The control cohort may not have had cancer at all
This isn't true. The group you're calling a control cohort (cohort 2) must all absolutely have cancer, and are all actively treated with the study drug (TSR-042).
If comment OP was trying to misinform on purpose, it’s a different story as there’s no opportunity for improvement there.
>> As with most experiments
>This isn't true. It's absolutely standard in earlier trials of investigational agents to not have any sort of control arm.
Can we agree that Clinical trials are a small subset of all experiments? And that Phase 1 isn't as large?
For your second two points you're correct and I agree with you.